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Santander, Vigo, Barcelona, Madrid, Valladolid, Oviedo, Leon, Malaga, Badalona, and Murcia, SpainObjectives This study sought to investigate the clinical impact of the use of intravascular ultrasound
(IVUS) during revascularization of patients with left main coronary artery (LM) disease with
drug-eluting stents (DES).
Background Whether the use of IVUS during the procedure adds a clinical beneﬁt remains unclear.
There is only 1 previous observational study, with relevant limitations, supporting the value of this
strategy.
Methods We performed a patient-level pooled analysis of 4 registries of patients with LM disease
treated with DES in Spain. A propensity score-matching method was used to obtain matched pairs of
patients with and without IVUS guidance.
Results A total of 1,670 patients were included, and 505 patients (30.2%) underwent DES implantation
under IVUS guidance (IVUS group). By means of the matching method, 505 patients without the use of
IVUS during revascularization were selected (no-IVUS group). Survival free of cardiac death, myocardial
infarction, and target lesion revascularization at 3 years was 88.7% in the IVUS group and 83.6% in the no-
IVUS group (p ¼ 0.04) for the overall population, and 90% and 80.7%, respectively (p ¼ 0.03), for the
subgroups with distal LM lesions. The incidence of deﬁnite and probable thrombosis was signiﬁcantly
lower in the IVUS group (0.6% vs. 2.2%; p¼ 0.04). Finally, IVUS-guided revascularization was identiﬁed as
an independent predictor for major adverse events in the overall population (hazard ratio: 0.70, 95%
conﬁdence interval: 0.52 to 0.99; p¼ 0.04) and in the subgroupwith distal lesions (hazard ratio: 0.54, 95%
conﬁdence interval: 0.34 to 0.90; p ¼ 0.02).
Conclusions The results of this pooled analysis show an association of IVUS guidance during
percutaneous coronary intervention with better outcomes in patients with LM disease undergoing
revascularization with DES. (J Am Coll Cardiol Intv 2014;7:244–54) ª 2014 by the American College of
Cardiology Foundation
Abbreviations
and Acronyms
DES = drug-eluting stent(s)
IVUS = intravascular
ultrasound
LM = left main coronary
artery
MI = myocardial infarction
PCI = percutaneous coronary
intervention
TLR = target lesion
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245Percutaneous revascularization of unprotected left main cor-
onary artery (LM) disease has been a controversial subject
during recent years. Even though LM treatment has been
traditionally reserved for surgery, there have been numerous
registries with drug-eluting stents (DES) that have shown
favorable outcomes (1–5). Randomized studies have shown
that percutaneous coronary intervention (PCI) of these le-
sions with paclitaxel and sirolimus-eluting stents, respectively,
may offer results comparable to surgery up to 3 years, as long as
the complexity and extent of the coronary disease are not high
(6–8). In a meta-analysis of randomized trials, PCI withDES
was associated with nonsigniﬁcantly different 1-year rates of
major adverse cardiac and cerebrovascular events, a lower risk
of stroke, and a higher risk of target vessel revascularization
compared with surgery (9).
This has resulted in LM PCI being included in clinical
guidelines as an alternative to surgery in cases when the latter
represents a high risk (10,11). The practice of PCI on un-
protected LM is increasing signiﬁcantly in Spain (12).
In this uniquely challenging anatomic scenario, the use of
intravascular ultrasound (IVUS) has been advocated as a means
to optimize procedural results with the hope that this may
translate into improved long-term clinical outcomes. However,
there is a dearth of appropriately-designed studies examining
whether a beneﬁt is derived from the use of IVUS during PCI
in patients with LM disease, and available recommendations
are mostly supported by retrospective registries and expert
opinion (13–15), without consistent results and subjected to
important limitations (16). The guideline recommendation for
using IVUS guidance during LM PCI is Class IIb (11).
In this study, we sought to investigate the clinical impact of
the use of IVUS in patients with LM disease undergoing PCI
with DES. For this purpose, we pooled data at the patient
level from 4 registries originally designed to evaluate outcomes
of patients with LM lesions treated with stents (17,18).
Methods
The present study consists of the pooled analysis of the
following Spanish LM registries:
1. ESTROFA-LM. ESTROFA-LM (Grupo Español
de Estudio de Stents Farmacoactivos: Left Main) wasFrom the *Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital
Marques de Valdecilla, Santander, Spain; yUnidad de Cardiología Intervencionista,
Servicio de Cardiología, Hospital Meixoeiro, Vigo, Spain; zUnidad de Cardiología
Intervencionista, Servicio de Cardiología, Hospital Bellvitge, Barcelona, Spain;
xUnidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Clinico
San Carlos, Madrid, Spain; kUnidad de Cardiología Intervencionista, Servicio de
Cardiología, Hospital de Valladolid, Valladolid, Spain; {Unidad de Cardiología
Intervencionista, Servicio de Cardiología, Hospital La Paz, Madrid, Spain; #Unidad
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Hospital 12 de Octubre, Madrid, Spain; yyUnidad de Cardiología Intervencionista,
Servicio de Cardiología, Hospital de Leon, Leon, Spain; zzUnidad de Cardiología
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patients treated with DES in 21 centers from 2004
to 2009. Patients with angiographically-signiﬁcant
lesions in unprotected LM treated with DES were
included. Only patients with cardiogenic shock at the
time of procedure were excluded. Patients had stable
or unstable ischemic heart disease, and LM lesions
that were considered signiﬁcant and with an indica-
tion for revascularization. Patients undergoing treat-
ment of lesions in other vessels were also included.
All clinical, angiographic, and procedural data were
reported in a common database speciﬁcally designed
for this study. At the same time, all information
about the clinical follow-up was also submitted and
adequately updated through registry and hospital
database reviews, as well as through contact with
patients. The 3-year follow-up outcomes have been
published elsewhere (17).
2. RENACIMIENTO. RENACIMIENTO (Registro
Nacional Sobre el Tratamiento del Tronco Común) was
a multicenter, prospective
registry performed at 30
hospitals in Spain. From
November 2007 to
November 2008, 1,493
consecutive patients with a
signiﬁcant angiographic
involvement of unprotected
LM, with indication of
revascularization, treated
with PCI or surgery were
included in a database. In
596 patients, DES were
implanted. For the purpose of the present analysis, pa-
tients with cardiogenic shock were excluded. This reg-
istry was designed for 1-year follow-up.
3. Bellvitge. In the Bellvitge registry, 236 consecutive
patients were included with angiographically-signiﬁcant
lesions in unprotected LM treated with stents in the
period from 2002 to 2010. Among these, 189 were
treated with DES. Exclusion criteria were patients
undergoing PCI in ST-segment elevation myocardial
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246infarction (MI) or in cardiogenic shock. The results of
this registry have been partially published (18). Plan-
ned follow-up was for 3 years.
4. Valdecilla. In the Valdecilla registry, 200 consecutive
patients with signiﬁcant lesions in unprotected LM
treated with DES from 2002 to 2010 were included.
There was no clinical or angiographic type of exclusion,
except for the presence of cardiogenic shock at the
time of procedure. Planned follow-up was for 3 years.
The ESTROFA-LM and RENACIMIENTO registries
were promoted and supported by the Spanish Working
Group of Interventional Cardiology of the Spanish Society
of Cardiology.
It is important to note that none of these 4 registries was
speciﬁcally designed to formally evaluate the efﬁcacy of
IVUS use in LM PCI; however, in all of them, information
regarding use of IVUS was systematically requested. Given
that some centers participated in 2 or 3 of these registries,
and there was a possibility for partial overlap during the
enrollment periods, we carefully searched for potential
duplicated inclusions (n ¼ 85), which were subsequently
deleted from the ﬁnal database. The 4 databases were pooled
and analyzed at the coordination center, Hospital Uni-
versitario Marques de Valdecilla, Santander, Spain, by 2 in-
vestigators (J.T.H., T.G.C.) blinded to group allocation.
There were no meaningful differences in the event deﬁnitions
among these studies, but events were adjudicated according to
the deﬁnitions ﬁnally provided in this paper that resulted from
a consensus. The pooling investigators reviewed every event
adjudication and the clinical data provided for patients with
adjudicated and not adjudicated events. Additional infor-
mation was requested and discussed with the corresponding
main investigators when any doubts existed, and re-adjudi-
cation was done in order to guarantee a homogeneous event
adjudication process.
Objectives and deﬁnitions. As has been indicated previ-
ously, these registries were not speciﬁcally designed to
address the role of IVUS in LM PCI. Therefore, there were
no speciﬁc IVUS criteria for device sizing, or identiﬁcation
and treatment of malapposition and/or underexpansion. The
decisions taken after the IVUS examination were left up to
the operator. The primary objective of the study was to
compare the major adverse cardiac event-free survival (car-
diac death, MI, and target lesion revascularization [TLR]) at
3 years between patients undergoing PCI with DES in LM
with IVUS guidance or with angiographic guidance alone.
Secondary objectives included: all-cause mortality, cardiac
mortality, survival free of infarction, survival free of TLR,
and incidence of deﬁnite and probable stent thrombosis.
The following major adverse cardiac events were deﬁned:
mortality as all-cause death; cardiac death as mortality from
cardiac etiologies such as infarction, heart failure, or stent
thrombosis, and including any sudden death by undeﬁnedcause; andMI. MI was deﬁned as: 1) detection of rise and fall
of cardiac biomarkers (preferably troponin) with at least 1
value above the 99th percentile of the upper reference limit
together with evidence of myocardial ischemia with at least 1
of the following: chest pain, electrocardiographic changes
(new ST-T changes or new left bundle branch block),
development of pathological Q waves, or new regional wall
motion or perfusion abnormalities; 2) sudden death involving
cardiac arrest, often with previous symptoms suggestive of
ischemia, and accompanied by presumably new ST-segment
elevation, or new left bundle branch block and/or evidence of
fresh thrombus in angiography and/or at autopsy, but death
occurring before blood samples could be obtained at a time
before the appearance of cardiac markers in blood; or 3)
pathological ﬁndings of an acute MI. PCI-related MI was
deﬁned as an increase of biomarkers >3 times the 99th
percentile of the upper reference limit.
TLR was deﬁned as revascularization for LM restenosis
(>50%), also including proximal or distal segments (5 mm)
adjacent to the stent or stents used for treatment of the
lesion, and including the ﬁrst distal 5 mm to the ostial left
anterior descending or circumﬂex arteries. Therefore, this
would consider a TLR to be an intervention upon a rest-
enotic lesion in the distal edge of a stent in LM that
extended to the proximal left anterior descending coronary
artery or upon the distal edge of a stent implanted in the
ostial–proximal left circumﬂex. Any surgical revasculariza-
tion as the result of restenosis as previously deﬁned was also
considered a TLR. Deﬁnite or probable stent thrombosis
was considered according to the deﬁnitions by the Academic
Research Consortium (19). It is deﬁnite when conﬁrmed by
angiography or when pathological conﬁrmation of acute
thrombosis is done in patients with acute coronary syn-
dromes. Probable stent thrombosis is deﬁned as any unex-
plained death within 30 days or as target vessel infarction
without angiographic conﬁrmation of thrombosis or other
identiﬁed culprit lesion.
Statistical analysis. Continuous variables are presented as
mean  SD. Categorical variables are expressed as per-
centages. Continuous variables were compared with the
Student t test if they followed a normal distribution, and
with Wilcoxon tests when they did not (assessment of type
of distribution by the Kolmogorov-Smirnov test). The cat-
egorical variables were compared with the chi-square test or
Fisher exact test, as required. Kaplan-Meier curves for
event-free survival were obtained for each group or subgroup
considered in the analysis and compared using the log-rank
test. Cox proportional hazard multiple regression analysis
was used to determine independent predictors of major
cardiac adverse events during the follow-up period. The
model included all variables that showed association with
major adverse cardiac events (death, infarction, and TLR)
in univariate analysis with a p value <0.1. In addition, we
also performed adjustment for differences in clinical,
Figure 1. Propensity-Score Matching Procedure
(A) Forest plot showing the odds ratio for cardiac death, infarction, and target
lesion revascularization in intravascular ultrasound (IVUS)-guided left main
coronary artery percutaneous coronary intervention in the registries (test for
heterogeneity: Q ¼ 2, degrees of freedom [df] ¼ 3, and p ¼ 0.57). (B) Absolute
standardized difference in means and density histograms before and after
matching (overall balance test: chi-square ¼ 13.4, df ¼ 17.0, and p ¼ 0.7).
Angio ¼ angiography; ESTROFA-LM ¼ Grupo Español de Estudio de Stents
Farmacoactivos: Left Main; RENACIMIENTO ¼ Registro Nacional Sobre el
Tratamiento del Tronco Común.
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247angiographic, and procedural characteristics by the use of
propensity score matching.
The “psmatching” customdialoguewas used in conjunction
with SPSS version 19 (IBM, Armonk, New York). The
psmatching programperforms all analyses inR (RFoundation
for Statistical Computing, Vienna, Austria) though the SPSS
R-Plugin (version 2.10.1). This procedure involved 3 stages:
1. The propensity scores were estimated using logistic
regression in which the use of IVUS was used as the
outcome variable and all covariates as predictors
(registry, age, sex, smoker, diabetes, hypertension,
hypercholesterolemia, chronic renal failure, left ven-
tricular ejection fraction, previous MI, previous PCI,
previous coronary artery bypass grafting, acute coro-
nary syndrome, MI, number of diseased vessels,
number of lesions treated, lesion location in LM,
diffuse lesion in LM, LM ulceration or dissection,
LM visual stenosis, LM stent length, LM stent
diameter, 2-stents technique, side-branch stent length,
side-branch stent diameter, rotational ablation,
glycoprotein IIb/IIIa inhibitors, angiographic success).
2. Patients were matched using simple 1:1 nearest
neighbormatching that is based on a “greedy”matching
algorithm that sorts the observations in the IVUS group
by their estimated propensity score. It then matches
each unit sequentially to a unit in the no-IVUS group
that has the closest propensity score. In order to exclude
bad matches, we imposed a caliper of 0.2 of the SD of
the logit of the propensity score. Units outside the area
of common support (deﬁned as the region of the dis-
tributions of estimated propensity scores in the IVUS
and no-IVUS groups for which units in both groups are
observed) were disregarded. This was done to improve
the balance of the covariates.
3. A series of model adequacy checks were performed to
check whether an adequate balance on the covariates
was achieved through the matching procedure. This
was done by computing the global imbalance measure
and through the production of 5 diagnostic plots: 1)
histograms of the propensity scores in both groups
before and after matching; 2) a dot plot of individual
propensity scores of units in the control and treatment
group, either matched or unmatched; 3) histograms of
the standardized differences of all terms (covariates,
quadratic term, interactions) before and after match-
ing; 4) a dot plot that displays the magnitude of the
standardized differences before and after matching for
each covariate; and 5) a line plot of standardized mean
differences before and after matching. An overall
imbalance chi-square test is provided. This test statistic,
which is related to the well-known Hotelling’s T2
statistic, assesses simultaneously whether any variable or
any linear combination of variables is signiﬁcantly
Table 2. Angiographic and Procedural Characteristics
IVUS
(n ¼ 505)
No IVUS
(n ¼ 505) p Value
2-vessel disease 160 (31.7) 168 (33.2) 0.6
3-vessel disease 161 (31.9) 149 (29.5) 0.4
Lesions treated 1.47  1.2 1.5  1.1 0.7
Ostial LM lesion 151 (30.0) 145 (28.7) 0.9
Mid-shaft LM lesion 133 (26.3) 134 (26.5) 0.8
Distal LM lesion 221 (43.7) 226 (44.7) 0.6
Diffuse LM disease 92 (18.2) 88 (17.4) 0.8
LM ulceration or dissection 79 (15.6) 69 (13.6) 0.4
LM visual stenosis, % 70.5  15.0 70.0  16.0 0.6
LM stent length, mm 16.0  5.4 16.8  5.7 0.08
LM stent diameter, mm 3.8  0.4 3.65  0.4 0.0001
Complex technique (2 stents) 63 (12.5) 62 (12.2) 0.9
2 stents/distal lesion 28.5 27.4 0.7
SB stent length, mm 15.8  5.0 16.2  4.0 0.2
SB stent diameter, mm 3.1  0.4 3.00  0.36 0.0001
Rotational ablation 21 (4.1) 22 (4.3) 0.9
GP IIb/IIIa inhibitors 83 (16.4) 92 (18.2) 0.5
Angiographic success 498 (98.6) 495 (98.0) 0.6
DAPT for at least 12 months 505 (100) 505 (100) 1.0
Values are mean  SD or n (%). Diseased vessel was deﬁned as a vessel with angiographic
stenosis 50% in a segment with a reference lumen diameter >2 mm. Lesion location in the
LM could be ostial (at the aorto-ostial junction), mid-shaft (at the mid-portion, not affecting the
ostium or bifurcation), or distal (lesion located at the bifurcation level of the LM).
DAPT ¼ dual antiplatelet therapy; GP ¼ glycoprotein; LM ¼ left main coronary artery;
SB ¼ side branch; other abbreviations as in Table 1.
Table 1. Clinical Characteristics
IVUS
(n ¼ 505)
No IVUS
(n ¼ 505) p Value
Age, yrs 66.1  11.6 66.9  11.5 0.4
Women 101 (20.0) 108 (21.3) 0.7
Current smoker 148 (29.3) 161 (31.8) 0.4
Diabetes 183 (36.2) 175 (34.6) 0.6
Hypertension 342 (67.7) 325 (64.3) 0.3
Hypercholesterolemia 314 (62.2) 284 (56.2) 0.2
Chronic renal failure 35 (6.9) 31 (6.1) 0.7
LVEF, % 54.9  12.5 55.3  13.0 0.6
Previous MI 122 (24.1) 130 (25.7) 0.6
Previous PCI 111 (21.9) 107 (21.2) 0.8
Previous CABG 15 (2.9) 18 (3.5) 0.7
ACS 298 (59.0) 308 (61.0) 0.5
MI 121 (23.9) 115 (22.7) 0.7
Values are mean  SD or n (%).
ACS ¼ acute coronary syndrome; CABG ¼ coronary artery bypass graft; IVUS ¼ intravascular
ultrasound; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; PCI ¼ percu-
taneous coronary intervention.
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248unbalanced after matching. The test examines all
covariates that were used to estimate the propensity
score.
A p value <0.05 was considered statistically signiﬁcant.
All statistical analyses were performed using SPSS version
19 for Windows.
Results
A total of 1,670 patients with LM disease treated with DES
were eventually included in the pooled ﬁnal database of the 4
registries. Among these, 505 patients (30.2%) underwent
PCI of the LM under IVUS guidance (IVUS group). The
use of IVUS was 27.7% in the RENACIMIENTO registry,
30.2% in the ESTROFA-LM registry (17), 21.7% in the
Bellvitge registry (18), and 45.5% in Valdecilla registry. The
odds ratio for major cardiac adverse events (cardiac death,
MI, and TLR) in patients with IVUS guidance for the
different registries is shown in Figure 1A. The use of IVUS
was associated with better outcomes in all registries, without
signiﬁcant heterogeneity.
By means of the propensity score-matching method, a
cohort of 505 patients treated without the use of IVUS
during PCI were selected (no-IVUS group). The adequacy
of propensity matching is illustrated in Figure 1B. The
c-statistic was 0.78.
Clinical characteristics of both groups are shown in
Table 1. The groups appeared well matched, and no sig-
niﬁcant differences were observed. Regarding angiographic
and procedural details, these are described in Table 2. The
only signiﬁcant differences noted were in stent diameter in the
LM and the side branch, most probably caused by the use ofIVUS to select the most appropriate stent size to be implanted.
All of the remaining characteristics were quite comparable.
The use of IVUS was designed to assess basal lesion
characteristics (severity, extension, calciﬁcation, and ostial
involvement) and then to guide PCI in 12% of patients. In
the remaining 88% of cases, IVUS was used to guide PCI,
allowing stent size selection after dilation, assessment of
stent coverage, expansion, and apposition, and evaluation of
the side branch ostium when needed. Even though we
included stent diameter and length in the propensity score-
matching process, diameters for the main and side branch
stents remained larger in the IVUS group. After IVUS ex-
amination, post-dilation (deﬁned as dilation with higher
pressure and/or larger balloon) was done in 40% of cases,
and a new stent was implanted in 7.9% of patients. This
information is not available for the angiography-guided
group in all registries. In the ESTROFA-LM (17) and
Valdecilla registries, post-dilation was signiﬁcantly more
frequently done in the IVUS-guided PCI group and was
accomplished with larger balloons compared with angiog-
raphy-guided PCI.
Curves for event-free survival in both groups are shown in
Figures 2 to 4. The incidences of major adverse events are
listed in Table 3. Survival free of the combined endpoint of
cardiac death, infarction, and TLR was signiﬁcantly better in
the IVUS group. Patients with IVUS had signiﬁcantly better
Figure 3. Outcomes for Overall Groups: MI and TLR
(A) Survival free of myocardial infarction (MI). (B) Survival free of target lesion
revascularization (TLR). Abbreviations as in Figure 2.
Figure 2. Outcomes for Overall Groups: All-Cause and Cardiac Death
(A) Survival free of all-cause death. (B) Survival free of cardiac death.
IVUS ¼ intravascular ultrasound; Pts ¼ patients.
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249survival, and they had lower all-cause mortality, but when
considering only cardiac death, there was a trend in favor of
IVUS guidance that did not reach signiﬁcance. MI and
TLR incidences were comparable in both groups. In addi-
tion, the incidence of deﬁnite and probable thrombosis was
signiﬁcantly lower in the IVUS group (0.6% vs. 2.2%; p ¼
0.04) (Fig. 5).
Subgroup analysis: distal lesions. In the subgroup of pa-
tients with distal lesions, survival free of major adverse events
(cardiac death, MI, and TLR) was signiﬁcantly better for the
IVUS group (Fig. 6, Table 3). This beneﬁt was driven by a
reduction in death, but not in infarction or TLR. Amongthose patients treated with 2 stents, the use of IVUS was
associated with a signiﬁcantly better outcome, even despite
the small numbers (Fig. 7, Table 3). However, in this
particular subset, a trend for a decreased TLR rate in the
IVUS group was observed.
Finally, independent predictors for major adverse events
are listed in Table 4. Notably, IVUS emerged as an inde-
pendent predictor for fewer adverse events in the overall
patient population and especially in the subgroup of patients
with distal LM disease.
In Figure 8, an illustrative case of deﬁnite stent thrombosis
after DES implantation without IVUS guidance is shown.
Table 3. Incidence of Major Adverse Events
IVUS No IVUS p Value
Overall, n 505 505
Death 7.4 13.0 0.01
Cardiac death 3.3 6.0 0.07
MI 4.5 6.5 0.4
TLR 7.7 6.3 0.7
Death þ MI þ TLR 14.4 22.2 0.006
Cardiac death þ MI þ TLR 11.7 16.0 0.04
Deﬁnite or probable stent thrombosis 0.6 2.2 0.04
Subgroup with distal lesions, n 221 226
Cardiac death þ MI þ TLR 11.0 19.0 0.03
Subgroup with distal lesions-2 stents, n 63 62
Cardiac death þ MI þ TLR 16.7 41.0 0.02
Values are %, except where otherwise indicated.
IVUS ¼ intravascular ultrasound; MI ¼ myocardial infarction; TLR ¼ target lesion
revascularization.
Figure 4. Outcomes for Overall Groups: MACE
(A) Survival free of all-cause death, MI, and TLR. (B) Survival free of cardiac
death, MI, and TLR. MACE ¼major adverse cardiac events; other abbreviations
as in Figures 2 and 3.
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250Findings in IVUS examination at the time of thrombosis
(underexpansion and malapposition) could have been iden-
tiﬁed and corrected in the index procedure, probably avoiding
stent thrombosis, a potentially fatal complication.
Discussion
The ﬁndings of this pooled analysis indicate that the use of
IVUS guidance for PCI with DES in patients with LM
lesions is associated with a better clinical outcome, especially
in those cases with distal LM disease. Importantly, this
beneﬁt was driven by reduction in mortality. The use ofIVUS was also associated with a lower risk of stent throm-
bosis. Finally, a trend for a lower TLR rate was observed
with the use of IVUS in patients requiring the implantation
of 2 stents.
We realize that the clinical beneﬁt associated with the
use of IVUS could have been partially explained by the
effect of confounders. However, our results show that IVUS
guidance allowed larger and more fully expanded stents.
Differences in stent thrombosis rates and a clinical beneﬁt
focused in distal lesions are in agreement with a plausible
IVUS-derived positive effect. Age, sex, diabetes, renal fail-
ure, ejection fraction, number of diseased vessels, number of
lesions treated, and other variables with prognostic relevance
were well matched. Patients selected for DES implantation,
especially at the LM level, are considered to be suitable for
long-term dual antiplatelet therapy. This criterion may have
prevented the inclusion in these registries of patients with
comorbidities related to a higher bleeding risk that may have
great inﬂuence on outcomes. Patients with cardiogenic
shock were excluded as well, because in these patients, the
goal is an emergent restoration of ﬂow at the LM level, and
the use of IVUS is much less frequently done. Finally, the
use of IVUS could be linked to a better operator’s proﬁle,
being a marker of a higher-quality performance.
The use of IVUS was similar in the larger nation-wide
registries (27.7% and 30.2%) andmore different in the single-
center registries (21.7% and 45.5%). Clinical outcomes in
these registries were fairly comparable, with a rate of survival
free of cardiac death, MI, and TLR at 1 year of 86% to 89%.
Follow-up was shorter in the RENACIMIENTO registry
(1 year). Nevertheless, the positive outcome associated with
the use of IVUS was consistent across the 4 registries, with no
signiﬁcant heterogeneity.
One of the most discussed issues in interventional cardi-
ology has been the strategy for revascularization in patients
Figure 6. Outcomes for the Subgroups With Distal LM Disease
(A) Survival free of cardiac death, MI, and TLR. (B) Survival free of TLR.
LM ¼ left main coronary artery; other abbreviations as in Figures 2 and 3.
Figure 5. Outcomes for Overall Groups: Stent Thrombosis
Incidence of deﬁnite and probable thrombosis. Abbreviations as in Figure 2.
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251with LM lesions. This is a setting in which surgery still
maintains its status as the ﬁrst-option strategy. Multiple
registries and 2 trials including patients treated with DES in
LM disease have been overall positive, although these results
depended to a great extent upon the type of lesion, and thus,
outcomes were not as excellent in distal lesions as in cases of
ostial or mid-shaft lesions (1–9). Thus, a Class IIb indica-
tion has been recently granted for percutaneous revascular-
ization of the LM in patients with favorable anatomy (11).
On the other hand, the role of IVUS guidance in PCI of
the LM has been highly controversial. In fact, the guidelines’
recommendation for using IVUS guidance during LM PCI
is Class IIb (11). The lack of speciﬁc randomized trials
focused on answering this question implies that current
evidence relies on retrospective analyses. In this regard,
conﬂicting results were initially reported in small registries
(13,20). However, signiﬁcant differences in patient and
procedural characteristics existed between these registries
that could explain the observed different inﬂuence of IVUS
guidance on clinical outcomes (5,21).
The most relevant contribution to this topic came from a
post-hoc analysis of the MAIN-COMPARE (Revasculari-
zation for Unprotected Left Main Coronary Artery Stenosis:
Comparison of Percutaneous Coronary Angioplasty Versus
Surgical Revascularization) study, which showed the outcome
in 145 “comparable” well-matched pairs of patients with andwithout IVUS guidance during PCI with DES (14). In this
analysis, the 3-year incidence of total mortality was lower in
the IVUS-guided group (4.7% vs. 16%; p ¼ 0.048) with
survival curves diverging beyond the second year. The use of
IVUS did not inﬂuence the incidence of MI or TLR.
However, there are some important limitations worthy of
discussion (16). In this registry, all baseline characteristics
were clearly favorable for the IVUS-guided arm. Despite
elegant, rigorous, and exhaustive adjustments (using pro-
pensity score-matching analyses), it remains possible that
some unmeasured confounders could also be more favorable
in the IVUS-guided arm, therefore explaining its better
outcome. This is relevant because of the potential presence of
Table 4. Independent Predictors for Major Adverse Events
HR 95% CI p Value
Overall population
IVUS 0.70 0.52–0.99 0.04
Age 1.03 1.01–1.05 0.0001
LVEF 0.98 0.97–0.99 0.01
Diabetes 1.81 1.32–2.47 0.0002
Distal LM with 2 stents 2.23 1.44–3.48 0.0004
ACS 1.84 1.30–2.60 0.0006
Subgroup with distal LM disease
IVUS 0.54 0.34–0.90 0.02
Age 1.02 1.004–1.05 0.02
Diabetes 1.62 1.02–2.59 0.04
Distal LM with 2 stents 2.86 1.71–4.77 0.0001
ACS 1.95 1.14–3.31 0.01
Subgroup with ostial-mid LM disease
Age 1.04 1.02–1.05 <0.0001
ACS 1.68 1.17–2.40 0.004
IVUS 0.85 0.55–1.15 0.2
Abbreviations as in Tables 1 and 2.
Figure 7. Outcomes for the Subgroups With Distal LM Disease Treated
With 2 Stents
(A) Survival free of cardiac death, MI, and TLR. (B) Survival free of TLR.
Abbreviations as in Figures 2, 3, and 6.
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252severe noncardiac comorbidities (difﬁcult to adjust for) in the
cohort of complex patients with angiographic-guidance
alone. Data on “total mortality” favoring IVUS guidance are
difﬁcult to interpret in the absence of comparative data on
cardiac mortality and stent thrombosis. The very late effect of
IVUS on survival results is also intriguing.
There are notable differences between our current study
and the MAIN-COMPARE study (14). After propensity
score matching, our population, coming from multicenter
nationwide registries, is signiﬁcantly larger, therefore
providing more statistical power and allowing subgroup
analyses (distal LM lesions and 2-stent subgroups). More-
over, the proportion of patients undergoing IVUS exami-
nation during PCI in our registries is not that high (77.5%vs. 30.2%) and more comparable to the average reported in
U.S. and European countries. Finally, data on cardiac
mortality and stent thrombosis are only available from our
study.
Our study shows similar results to the MAIN-
COMPARE study, suggesting that IVUS guidance is asso-
ciated with signiﬁcantly lower mortality and similar TLR at
follow-up. However, the present study provides further in-
sights into these general ﬁndings. The difference in all-cause
mortality is signiﬁcant, but this is to some extent related to
differences in cardiac causes. Interestingly, in our study the
use of IVUS was associated with a lower thrombosis risk.
However, despite the use of the Academic Research Con-
sortium deﬁnitions for stent thrombosis, the incidence of
this event may have been underestimated, because this
complication at the LM location may easily present as
sudden death. On the other hand, there seems to be an
apparent disconnect between infarction and thrombosis
rates; although there is a signiﬁcant reduction in thrombosis
rates with IVUS, the incidence of infarction is comparable.
This is due to the fact that most of the infarctions occurring
in follow-up were related to locations other than the LM.
Another important ﬁnding is that most of the clinical beneﬁt
related to IVUS use occurs early after intervention (<60
days). This makes sense and would lend support to the
contention that IVUS assists by improving acute outcomes.
In the subgroup of patients with distal lesions, and spe-
ciﬁcally in those treated with 2 stents, the differences be-
tween groups were even more evident and remained
statistically signiﬁcant despite the smaller numbers. It is well
known that these patients have a higher risk for thrombotic
Figure 8. Case Corresponding to the No-IVUS Cohort
This patient underwent drug-eluting stent (DES) implantation (4/12 mm) in the LM without IVUS guidance; 20 days later, the patient was admitted with non–
ST-segment elevation acute coronary syndrome. (A) Angiography with ﬁnal result after DES implantation. (B) Angiography showing a nonocclusive thrombus within
the stent (arrow). (C) Angiography after post-dilation of the stent. (D) IVUS imaging revealed stent subexpansion and distortion (short arrows) that was due to an
eccentric calciﬁed plaque, stent malapposition (long arrow), and thrombus (dashed arrow) at that level. (E) After dilation with a noncompliant balloon (4.5/8 mm) at
high pressure (18 atm), stent expansion, geometry, and apposition were improved. Abbreviations as in Figures 1 and 6.
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253events and worse outcome compared with patients with
nondistal LM lesions. It seems reasonable then to suggest
that that the use of IVUS provides a greater beneﬁt in this
setting. We found that IVUS guidance did not reduce TLR.
Only a trend in this regard was found in the subset of pa-
tients treated with 2 stents. This may be partially due to the
low rate of TLR observed in these registries using DES and
not mandating routine angiographic surveillance in asymp-
tomatic patients. On the other hand, because the use of
IVUS was at the discretion of the operator, the use of IVUS
might be selected for more complex anatomy.
Study limitations. This is a retrospective comparative reg-
istry with baseline differences between groups. Registries
entail limitations, particularly the problem of bias secondary
to known and unknown confounding factors not always
being sorted out even after careful adjustments with matched
analyses such as the propensity score. Despite propensityscore matching, it still remains possible that some unmea-
sured confounders could favor the IVUS-guided arm,
explaining its better outcome.
None of the registries was speciﬁcally designed to evaluate
the inﬂuence of IVUS on outcomes. Therefore, there were no
speciﬁc IVUS criteria for device sizing or identiﬁcation and
treatment of malapposition and/or underexpansion. This is a
limitation in order to know how IVUS affected the procedure,
leading to improved outcomes. The decisions taken after
IVUS examination were left up to the operator. The registries
had different follow-up lengths and rate of IVUS usage;
however, the use of IVUS guidance was associated homoge-
nously with better outcomes in all the registries.
Characterization of distal LM disease could have been
more detailed (e.g., Medina classiﬁcation). The SYNTAX
score was not recorded because this tool was not widely
available when these registries started.
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254Conclusions
The results of this pooled analysis of multiple large registries
suggest a positive clinical impact of the use of IVUS guid-
ance during PCI of LM lesions with DES, especially when
lesions affect the bifurcation.
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